# First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies

> **NCT01971515** · PHASE1 · COMPLETED · sponsor: **EMD Serono** · enrollment: 101 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** MSC2363318A
- **DRUG:** MSC2363318A plus Trastuzumab
- **DRUG:** MSC2363318A plus Tamoxifen

## Key facts

- **NCT ID:** NCT01971515
- **Lead sponsor:** EMD Serono
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-13
- **Primary completion:** 2018-08-09
- **Final completion:** 2018-08-09
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2018-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01971515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01971515, "First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01971515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*